New stock news | Mingyu Pharmaceutical submits application to Hong Kong Stock Exchange again
According to the Hong Kong Stock Exchange's disclosure on July 8th, Miric Pharmaceutical Limited-B (referred to as Miric Pharmaceuticals) has once again submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities serving as its joint sponsors.
According to the disclosure by Hong Kong Stock Exchange on July 8, Mingyu Pharmaceutical Limited-B (referred to as Mingyu Pharmaceutical) has once again submitted its listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as its joint sponsors. According to the prospectus, the company was established in 2018 and is a biotechnology company focusing on integrated oncology, with a research focus on the development of Antibody-Drug Conjugates (ADC) and advanced immunotherapy. As of the latest practicable date (July 1, 2026), the company's research pipeline includes 11 candidate products, including two core products.
Related Articles
SINOPEC SEG (02386) plans to repurchase H-shares.
SINOPEC SEG (02386) will distribute an interim dividend of 0.127 yuan per share on October 30.
GenScript BIO (01548) released its mid-term results, with a shareholder loss of $129 million, narrowing by 29.25% year-on-year.
SINOPEC SEG (02386) plans to repurchase H-shares.
SINOPEC SEG (02386) will distribute an interim dividend of 0.127 yuan per share on October 30.
GenScript BIO (01548) released its mid-term results, with a shareholder loss of $129 million, narrowing by 29.25% year-on-year.
RECOMMEND
